SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) CF (Heat Inactivated)0810623CFHI
SARS-Related Coronavirus 2 Lineage B.1.617.2; Kappa Variant (Isolate: USA/CA-Stanford-15_S02/2021) is an enveloped, positive-sense single-stranded RNA virus from the Coronaviridae family and the Betacoronaviridae genus. Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/CAStanford-15_S02/2021 (also referred to as hCoV19/USA/CA-SU-15_S02/2021) was isolated from a midturbinate nasal swab from a 29-year-old male in California, USA on March 5, 2021. Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate hCoV-19/USA/CA-Stanford-15_S02/2021 is assigned lineage B.1.617.1 and GISAID clade G using Phylogenetic Assignment of Named Global Outbreak LINeages (PANGOLIN) tool. SARS-CoV-2, lineage B.1.617.1 was first detected in India and labelled as a variant of interest (VOI). It was labelled as Kappa variant by the World Health Organization (WHO). The complete genome of SARS-CoV-2, isolate hCoV-19/USA/CAStanford-15_S02/2021 has been sequenced (GISAID: EPI_ISL_1675223).
Each frozen aliquot contains 1 mL of heat inactivated viral culture fluid. The culture fluid was clarified prior to heat inactivation by centrifugation to remove cellular debris. The pre-inactivation titer was determined from an infectious aliquot.
Viral inactivation is verified after heat inactivation by the absence of viral growth in tissue culture-based infectivity assays.
Heat inactivated viral culture fluids are sold as consumable testing materials. The suitability and performance characteristics should be determined by your laboratory for each intended usage.